key: cord-0705176-8ak72zie
authors: Zhang, Fen; Wan, Yating; Zuo, Tao; Yeoh, Yun Kit; Liu, Qin; Zhang, Lin; Zhan, Hui; Lu, Wenqi; Xu, Wenye; Lui, Grace C.Y.; Li, Amy Y.L.; Cheung, Chun Pan; Wong, Chun Kwok; Chan, Paul K.S.; Chan, Francis K.L.; Ng, Siew C.
title: Prolonged impairment of short-chain fatty acid and L-isoleucine biosynthesis in gut microbiome in patients with COVID-19
date: 2021-10-21
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.10.013
sha: 9de24c23b03a0b1a8b263fbda3fc4f718495c2bc
doc_id: 705176
cord_uid: 8ak72zie

Background & Aims SARS-CoV-2 infection is associated with altered gut microbiota composition. Phylogenetic groups of gut bacteria involved in the metabolism of short chain fatty acids were depleted in SARS-CoV-2-infected patients. We aimed to characterize functional profile of gut microbiome in patients with COVID-19 before and after disease resolution. Methods We performed shotgun metagenomic sequencing on fecal samples from 66 antibiotics-naïve patients with COVID-19 and 70 non-COVID-19 controls. Serial fecal samples were collected (up to 6 times points) during hospitalization and beyond one month after discharge. We assessed gut microbial pathways in association with disease severity and blood inflammatory markers. We also determined changes of microbial functions in fecal samples before and after disease resolution and validated these functions using targeted analysis of fecal metabolites. Results Compared with non-COVID-19 controls, COVID-19 patients with severe/critical illness showed significant alterations in gut microbiome functionality (P < .001), characterized by impaired capacity of gut microbiome for short chain fatty acid (SCFA) and L-isoleucine biosynthesis and enhanced capacity for urea production. Impaired SCFA and L-isoleucine biosynthesis in gut microbiome persisted beyond 30 days after recovery in COVID-19 patients. Targeted analysis of fecal metabolites showed significantly lower fecal concentrations of SCFAs and L-isoleucine in COVID-19 patients before and after disease resolution. Lack of SCFA and L-isoleucine biosynthesis significantly correlated with disease severity and increased plasma concentrations of CXCL-10, NT-proBNP, C-reactive protein (CRP) (all P < .05). Conclusions Gut microbiome of COVID-19 patients displayed impaired capacity for SCFA and L-isoleucine biosynthesis which persisted even after disease resolution. These two microbial functions correlated with host immune response underscoring the importance of gut microbial functions in SARS-CoV-2 infection pathogenesis and outcome.

Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily infects the respiratory system but also affects other organs including the gastrointestinal (GI) tract [1] [2] [3] [4] . Recent studies have reported altered gut microbiome in SARS-CoV-2 infection [5] [6] [7] , characterized by depletion of beneficial (butyrate-producing) bacteria, such as several genera from the Ruminococcaceae and Lachnospiraceae families and enrichment of opportunistic pathogens including Streptococcus, Rothia, Veillonella, and Actinomyces 8 . These alterations persisted even after recovery from COVID-19. Underrepresentation of several gut commensals with known immunomodulatory potential in fecal samples of COVID-10 patients including Faecalibacterium prausnitzii, Eubacterium rectale and Bifidobacterium reflects disease severity and dysfunctional host immune responses 9 .

The gut microbiota is known to regulate host immune responses to respiratory viral infections [10] [11] [12] . Metabolites secreted by gut microbiome (such as tyrosine) could protect from influenza through the production of type I interferons and inflammasomedependent cytokines by pulmonary cells 13, 14 . Whether microbial-derived metabolites also regulate host immune response to SARS-COV-2 infections remain unknown.

Interestingly, an in vitro experiment demonstrated that butyrate downregulated genes essential for SARS-CoV-2 infection such as angiotensin-converting enzyme 2 (ACE2) and upregulated TLR (toll-like receptor) antiviral pathways in gut epithelial organoids 15 .

Important microbial activities are a reflection of cumulative functions of the whole community of gut microbiota and the balance of the community and its output determines the net contribution to health or disease 16 . Deciphering the role of microbial-derived butyrate or other metabolites in SARS-CoV-2 pathogenesis and severity can shed light on our understanding of possible mechanistic links between gut microbiota and host defense against SARS-CoV-2.

In this study, we prospectively recruited 66 antibiotic treatment-naïve patients with COVID-19 and followed them up from hospital admission until 30 days after discharge.

We characterized alterations and longitudinal dynamics of the functions of the gut microbiome in association with disease severity and immune response using metagenomic analysis. We further validated our findings using targeted metabolomics analysis to examine alterations in fecal microbial metabolites.

This study was approved by the Clinical Research Ethics Committee (reference number 2020.076), and all patients provided written informed consent. As described in our previous study 17, 18 , COVID-19 subjects were recruited at the Prince of Wales and United Christian Hospitals in Hong Kong. Inclusion criteria included: SARS-CoV-2 RT-PCR positive based on respiratory specimens, hospitalized, and had no probiotics, prebiotics and antibiotics use within 3 months before enrollment. Patients were classified into four severity groups based on symptoms as reported by Wu et al 11 .

Briefly, patients were classified as mild if there were no radiographic indications of pneumonia, moderate if pneumonia with fever and respiratory tract symptoms were detected, severe if respiratory rate ≥30 breaths per minute, oxygen saturation ≤93% when breathing ambient air, or PaO2/FiO2 ≤300 mmHg, critical if respiratory failure requiring mechanical ventilation or organ failure requiring intensive care. Blood and stools from hospitalized patients were collected by hospital staff while discharged patients provided stools during follow-up visits. Samples were stored at -80 °C until processing. The pneumonia controls who were hospitalized with community-acquired pneumonia were recruited. Inclusion criteria included: SARS-CoV-2 RT-PCR negative based on respiratory specimens, hospitalized, and had no probiotics, prebiotics and antibiotics use within 3 months before enrollment. The non-COVID-19 subjects were J o u r n a l P r e -p r o o f recruited at the Prince of Wales Hospital in Hong Kong from the general population in 2019 before the pandemic as part of a microbiome survey. Inclusion criteria included: 18 years of age or older, had not used probiotics, prebiotics or antibiotics within 3 months before enrollment.

Detailed methods are described in Zuo et al 17 Concentration of N-terminal proBNP (NT-proBNP) was measured using Human NT-proBNP ELISA kits (Abcam, Cambridge, UK).

The quantification of fecal metabolites was performed by Metware Biotechnology Co., 

Data on the abundance of bacterial taxa and functionality were imported into R v3.5.1. and mild (47.0%, n=31), according to the COVID-19 severity classification criteria 26 .

To understand how SARS-CoV-2 infection influences gut microbiome in antibiotics- test, Figure 2C ). Diet over the course of hospitalization (Supplementary Table 3 ) did not show significant effect in the variation of microbial functional pathway (PERMANOVA test, R 2 = 0.01, P = 0.23, Figure 2C ). In addition, COVID-19 patients showed significantly lower richness of microbial pathways in their feces compared with non-COVID-19 controls ( Figure 2D , P < .05). These results suggest that SARS-COV-2 infection is associated with altered functional profile of gut microbiome as well.

We next interrogated which microbial functions primarily drive the difference in COVID- showed significantly positive correlation with COVID-19 severity ( Table 2 , FDR corrected p-value < .2). Sugar derivative degradation was associated with production of pyruvate which is the key metabolite for short chain fatty acid fermentation 27, 28 . Lisoleucine are crucial mediator in the microbiota-host crosstalk and play important roles in regulating host innate and adaptive immunity [29] [30] [31] . Alterations in the microbial functions in the gut of COVID-19 patients may have a significant impact in host physiology and functions.

To determine whether hospitalization may contribute to changes of gut microbiome, we have also included patients hospitalized with community-acquired pneumonia but were negative for COVID-19 (Supplementary Table 5 ). We found that patients with COVID- (Figure 3 ). Low platelet count was associated with increased risk of severe disease and mortality in COVID-19 37 . Hence, overexpression of these two pathways may be associated with more dysfunctional immune responses. Altogether, our data highlight that gut microbiome might functionally calibrate host immunity against SARS-CoV-2 infection thereby affecting COVID-19 severity.

To explore whether gut microbiome and their functions was restored in patients after controls ( Figure 4C ). We then investigated whether differential taxa (showed in Supplementary Figure 4D ). These data suggest that gut microbiome functionality in patients persistently impaired after COVID-19 resolution.

Fecal metabolome provides a functional readout of microbial activity and can be used as a medium for mediating host-microbiome interaction 38 . Based on targeted analysis of fecal metabolites in COVID-19 patients and controls, we found that the changes of gut microbial functions were consistent with alterations of gut microbial metabolites.

Several pathways associated with production of SCFAs and L-isoleucine were depleted in patients with COVID-19, especially in those severe/critical patients (Supplementary Table 4 and Table 2 ). We found fecal concentrations of SCFAs, including acetic acid, propionic acid, butyric acid, valeric acid and caproic acid, were significantly lower in COIVD-19 patients with severe/critical illness at baseline (the first stool sample collected after admission) than that in non-COVID-19 controls ( Figure   6A -G). The concentrations of L-isoleucine in COVID-19 patients were lower than that in controls as well (P <.05, Figure 6H ) Furthermore, gut-microbiota-dependent urea metabolism are known to correlate with host urea balance and is implicated in disease progression 47 . We found that gut patients with non-COVID-19 controls was determined by Mann-Whitney U test, and was indicated as # P < .05. 

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov

Infectious SARS-CoV-2 in feces of patient with severe COVID-19

Immunodepletion with hypoxemia: a potential high risk subtype of coronavirus disease 2019

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization

Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge

Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Microbiota regulates immune defense against respiratory tract influenza A virus infection

Gut microbiota and Covid-19-possible link and implications

Commensal bacteria calibrate the activation threshold of innate antiviral immunity

The microbial metabolite desaminotyrosine protects from influenza through type I interferon

Peptidoglycan-associated cyclic lipopeptide disrupts viral infectivity

Butyrate Regulates COVID-19-Relevant Genes in Gut Epithelial Organoids from Normotensive Rats

The role of the gut microbiota in nutrition and health

Alterations in Gut Microbiota of patients with

Trimmomatic: a flexible trimmer for Illumina sequence data

Species-level functional profiling of metagenomes and metatranscriptomes

Metagenomic biomarker discovery and explanation

Fast gapped-read alignment with Bowtie 2

Fast and sensitive protein alignment using DIAMOND

UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches

The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases

Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study

The short-chain fatty acid acetate in body weight control and insulin sensitivity

Human milk from atopic mothers has lower levels of short chain fatty acids

Metabolism of dietary and microbial vitamin B family in the regulation of host immunity

Isoleucine plays an important role for maintaining immune function

L-isoleucine administration alleviates rotavirus infection and immune response in the weaned piglet model

COVID-19: consider cytokine storm syndromes and immunosuppression

Prognostic value of NT-proBNP in patients with severe COVID-19

COVID-19 pulmonary and olfactory dysfunctions: is the chemokine CXCL10 the common denominator?

Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19

Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis

The fecal metabolome as a functional readout of the gut microbiome

Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

The role of short-chain fatty acids in immunity, inflammation and metabolism

Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity

A review of the relationship between the gut microbiota and amino acid metabolism

Effect of BCAA supplementation on central fatigue, energy metabolism substrate and muscle damage to the exercise: a systematic review with meta-analysis

Effects of Oral Branched-Chain Amino Acids (BCAAs) Intake on Muscular and Central Fatigue During an Incremental Exercise

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Green tea polyphenols boost gut-microbiotadependent mitochondrial TCA and urea cycles in Sprague-Dawley rats

Proteomic and metabolomic characterization of COVID-19 patient sera

The authors characterized functional profile of gut microbiome and examined fecal metabolites in patients COVID-19 before and after disease resolution. New Findings COVID-19 patients displayed impaired capacity for short-chain fatty acid (SCFA) and L-isoleucine biosynthesis in their gut microbiome which persisted after recovery and correlated with disease severity and host immune responses

Limitations It is an observational study without clear cause or consequence effect established

biosynthesis in COVID-19 before and after disease resolution. Strategies to supplement SCAF or L-isoleucine might be developed to improve disease outcome

Gut microbiome of COVID-19 patients displayed impaired capacity for SCFAs and L-isoleucine biosynthesis. Further studies are needed to understand how impaired gut microbial functions are involved in disease outcome